Role of fenofibrate alone and in combination with telmisartan on renal ischemia/reperfusion injury

REFERENCES

• Kumai T, Oonuma S, Kitaoka Y Biochemical and morphological characterization of spontaneously hypertensive hyperlipidemic rats. Clin Exp Pharmacol Physiol. 2003;30:537–544. doi: 10.1046/j.1440–1681.2003.03872.x.
   PubMedGoogle Scholar
• Bhalodia Y, Sheth N, Vaghasiya J, Jivani N. Hyperlipidemia enhanced oxidative stress and inflammatory response evoked by renal ischemia/reperfusion injury. Int J Pharmacol. 2010; 6(1):25–30.
   Google Scholar
• Yellon DM, Baxter GF. Protecting the ischemic and reperfused myocardium in acute myocardial infarction: Distant dream or near reality? Heart. 2000;83:381–387. doi: 10.1136/heart.83.4.381.
   PubMed Web of Science ®Google Scholar
• Anja SM, Min WS, Kelly LH, Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice. Kidney Int. 2004;66: 1393–1402. doi:10.1111/j.1523–1755.2004.00854.x.
   PubMedGoogle Scholar
• Edelstein CL, Ling H, Schrier RW. The nature of renal cell injury. Kidney Int. 1997;51:1341–1351.
   PubMed Web of Science ®Google Scholar
• Seujange Y, Eiam-Ong S, Tirawatnapong T, Eiam-Ong S. Role of angiotensin II on dihydrofolate reductase, GTP-cyclohydrolase 1 and nitric oxide synthase expressions in renal ischemia-reperfusion. Am J Nephrol. 2008;28:692–700.
   PubMed Web of Science ®Google Scholar
• Park JK, Mervaala EM, Muller DN, Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion. J Hypertens. 2009;27:599–605.
   PubMedGoogle Scholar
• Prathapasinghe GA, Siow YL, Karmin O. Detrimental role of homocysteine in renal ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2007;292:1354–1363.
   PubMedGoogle Scholar
• Toyama T, Nakamura H, Harano Y, PPAR alpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem Biophys Res Commun. 2004;324:697–704.
   PubMed Web of Science ®Google Scholar
• Patel NS, di Paola R, Mazzon E, Peroxisome proliferator-activated receptor-alpha contributes to the resolution of inflammation after renal ischemia/reperfusion injury. J Pharmacol Exp Ther. 2009;328:635–643.
   PubMedGoogle Scholar
• Mandarim-de-Lacerda CA, Pereira LM. Effects of telmisartan on preexistent cardiac and renal lesions in spontaneously hypertensive mature rats. Histol Histopathol. 2004;19:727–733.
   PubMed Web of Science ®Google Scholar
• Tsunenari I, Ohmura T, Seidler R, Renoprotective effects of telmisartan in the 5/6 nephrectomised rats. J Renin Angiotensin Aldosterone Syst. 2007;8:93–100.
   PubMed Web of Science ®Google Scholar
• Cibulskyte D, Pedersen M, Hørlyck A, Telmisartan attenuates chronic ciclosporin A nephrotoxicity in a pig model. Nephrol Dial Transplant. 2007;22:369–375.
   PubMed Web of Science ®Google Scholar
• Benson SC, Pershadsingh HA, Ho C, Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-γ modulating activity. Hypertension. 2004;43:993–1002.
   PubMed Web of Science ®Google Scholar
• Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R. Antiinflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis. 2008;198:22–28.
   PubMed Web of Science ®Google Scholar
• Kakuta H, Sudoh K, Sasamatsu M, Yamagishi S. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor blockers. Int J Clin Pharm Res. 2005;25:41–46.
   PubMedGoogle Scholar
• Bhalodia Y, Sheth N, Vaghasiya J, Jivani N. Cardiac damage induced by renal ischemia/reperfusion injury in hyperlipidemic rats: Role of PPAR-α agonist. Hong Kong J Nephrol. 2009;11(2):59–65.
   Google Scholar
• Fouad AA, Qureshi HA, Ibrahim Al-Sultan A, Yacoubi MT, Al-Melhim WN. Nephroprotective effect of telmisartan in rats with ischemia/reperfusion renal injury. Pharmacology. 2010;85:158–167. doi: 10.1159/000269779.
   PubMed Web of Science ®Google Scholar
• Kumari CS, Govindasamy S, Sukumar E. Lipid lowering activity of Eclipta prostrate in experimental hyperlipidemia. J Ethnopharmacol. 2006;105:332–335. doi: 10.1016/j.jep.2005.10.031.
   PubMed Web of Science ®Google Scholar
• Kontogiannis J, Burns KD. Role of AT1 angiotensin II receptors in renal ischemic injury. Am J Physiol Renal Physiol. 1998; 274(43):79–90.
   Google Scholar
• Slater TF, Sawyer BC. The stimulatory effects of carbon tetrachloride and other halogenoalkanes or peroxidative reactions in liver fractions in vitro. Biochem J. 1971; 123:805–814.
   PubMed Web of Science ®Google Scholar
• Moran MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta. 1979;582:567. doi: 10.1016/0304-4165(79):90289–7.
   Google Scholar
• Guevara I, Iwanejko J, Dembinska-Kiec A. Determination of nitrite/nitrate in human biological material by the simple Griess reaction. Clin Chim Acta. 1998;274:177–188. doi: 10.1016/S0009–8981(98)00060-6.
   PubMed Web of Science ®Google Scholar
• Wei H, Frenkel K. Relationship of oxidative events and DNA oxidation in SENCAR mice to in vivo promoting activity of phorbol ester-type tumor promoters. Carcinogenesis. 1993;14:1195–1201.
   PubMed Web of Science ®Google Scholar
• Cau J, Favreau F, Zhang K, FR167653 improves renal recovery and decreases inflammation and fibrosis after renal ischemia reperfusion injury. J Vasc Surg. 2009;49:728–740.
   PubMed Web of Science ®Google Scholar
• Korkmaz A, Kolankaya D. The protective effects of ascorbic acid against renal ischemia reperfusion injury in male rats. Ren Fail. 2009;31:36–43.
   PubMed Web of Science ®Google Scholar
• Volti GL, Sorrenti V, Murabito P, Pharmacological induction of heme oxygenase-1 inhibits iNOS and oxidative stress in renal ischemia-reperfusion injury. Transplant Proc. 2007;39:2986–2991.
   PubMed Web of Science ®Google Scholar
• Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci. 2003;24:471–478.
   PubMed Web of Science ®Google Scholar
• Neto JS, Nakao A, Kimizuka K, Protection of transplant-induced renal ischemia-reperfusion injury with carbon monoxide. Am J Physiol Renal Physiol. 2004;287:979–989.
   PubMed Web of Science ®Google Scholar
• Jia RP, Zhu JG, Wu JP, Xie JJ, Xu LW. Experimental study on early protective effect of ischemic preconditioning on rat kidney graft. Transplant Proc. 2009;41:69–72.
   PubMedGoogle Scholar
• Salom MG, Cerón SN, Rodriguez F, Heme oxygenase-1 induction improves ischemic renal failure: Role of nitric oxide and peroxynitrite. Am J Physiol Heart Circ Physiol. 2007;293: 3542–3549.
   PubMed Web of Science ®Google Scholar
• Guven A, Uysal B, Akgul O, Scavenging of peroxynitrite reduces renal ischemia/reperfusion injury. Ren Fail. 2008; 30:747–754.
   PubMed Web of Science ®Google Scholar
• Yeh C-H, Chen T-P, Lee C-H, Wu Y-C, Lin Y-M, Lin PJ. Cardiomyocytic apoptosis following global cardiac ischemia and reperfusion can be attenuated by peroxisome proliferatory activated receptor α but not γ activators. Shock. 2006;26(3):262–270. doi: 10.1097/01.shk.0000225863. 56714.96.
   PubMedGoogle Scholar
• Hou X, Shen YH., Li C, Wang F, Zhang C, Bu P, Zhang Y. PPARa agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity. Biochem Biophys Res Commun. 2010;394(3):653–659. doi:10.1016/j.bbrc.2010.03.043.
   PubMedGoogle Scholar
• Jung KH, Chu K, Lee ST, Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage. J Pharmacol Exp Ther. 2007;322:1051–1058.
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Ohno T, Yoshida K, Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in Dahl salt-sensitive hypertensive rats. Am J Hypertension. 2008;21:576–581.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Keep RF, Hua Y, Hoff JT, Xi G. Oxidative DNA injury after experimental intracerebral hemorrhage. Brain Res. 2005;1039:30–36.
   PubMed Web of Science ®Google Scholar
• Blessing E, Preusch M, Kranzhöfer R, Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis. 2008;199:295–303.
   PubMedGoogle Scholar
• Dimitropoulou C, Chatterjee A, McClud L, Tetik-Anacak G, Catravas JD. Angiotensin, bradykinin and the endothelium. In: Moncada S, Higgs A, eds. The Vascular Endothelium, Vol. I. Berlin: Springer; 2006:255–290.
   Google Scholar
• Mehta PK, Griendling KK. Angiotensin II cell signalling: Physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:82–97.
   PubMed Web of Science ®Google Scholar
• Prathapasinghe GA, Siow YL, Xu Z, Karmin O. Inhibition of cystathionine-β-synthase activity during renal ischemia-reperfusion: Role of pH and nitric oxide. Am J Physiol Renal Physiol. 2008;295:912–922.
   PubMedGoogle Scholar
• Dierkes J, Westphal S, Luley S. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet. 1999; 354:219–220.
   PubMed Web of Science ®Google Scholar
• Auwerx J, Schoonjans K, Fruchart JC, Staels B. Transcriptional control of triglyceride metabolism: Fibrates and fatty acids change the expression LPL and apoC-III genes by activating the nuclear receptor PPAR. Atherosclerosis. 1996; 124:29–37.
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-α activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol. 1999;10:245–257.
   PubMed Web of Science ®Google Scholar